Agomab Therapeutics NV announced the closing of a $100 million Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences, Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
October 11, 2023
· 3 min read